Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma

Published:2020-04 Issue:2 Volume:18 Page:e83-e90
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Di Nunno Vincenzo,Mollica Veronica,Schiavina Riccardo,Nobili Elisabetta,Fiorentino Michelangelo,Brunocilla Eugenio,Ardizzoni Andrea,Massari Francesco^ORCID

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference16 articles.

1. Cancer statistics, 2019;Siegel;CA Cancer J Clin,2019

2. Systemic therapy for metastatic renal-cell carcinoma;Choueiri;N Engl J Med,2017

3. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

4. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

5. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of modern immunotherapy in combination treatment of patients with renal cancer and bone metastases;Cancer Urology;2024-08-15

2. Exploring the detailed role of interleukins in cancer: A comprehensive review of literature;Pathology - Research and Practice;2024-05

3. Artificial Intelligence in Renal Cell Carcinoma Histopathology: Current Applications and Future Perspectives;Diagnostics;2023-07-06

4. Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective–prospective cohort multicentre study;Journal of Cancer Research and Clinical Oncology;2023-02-27

5. Prognostic Factors in Advanced Renal Cell Carcinoma;Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma;2023